ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.

Bittar, Peter G

Nickolich, Myles S

Onwuemene, Oluwatoyosi A

2023-04-07T13:48:19Z

2023-04-07T13:48:19Z

2018-06

2023-04-07T13:48:19Z

In the implementation of American Society for Apheresis national guidelines, the decision for therapeutic plasma exchange may be confounded by a clinical presentation that fits both a Category I and IV designation. We report the case of a 45-year-old female who presented with concern for a Category IV disorder, gemcitabine-induced thrombotic microangiopathy, and was ultimately diagnosed with a Category I disorder, idiopathic thrombotic thrombocytopenic purpura. This case highlights the importance of ruling out idiopathic TTP by a thorough evaluation for ADAMTS13 activity and inhibitor, even when an alternate thrombotic microangiopathy diagnosis may be likely.

0733-2459

1098-1101

https://hdl.handle.net/10161/27021

eng

Wiley

Journal of clinical apheresis

10.1002/jca.21590

Humans

Purpura, Thrombotic Thrombocytopenic

Thrombocytopenia

Deoxycytidine

Diagnosis, Differential

Plasma Exchange

Middle Aged

Female

Practice Guidelines as Topic

Thrombotic Microangiopathies

ADAMTS13 Protein

Gemcitabine

ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.

Journal article

Onwuemene, Oluwatoyosi A|0000-0001-7266-7101

423

426

3

Duke

School of Medicine

Clinical Science Departments

Medicine

Medicine, Hematology

Published

33